medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2022, Number 2

<< Back Next >>

Rev Latin Infect Pediatr 2022; 35 (2)

Antibiotic treatment of Clostridioides difficile infection in children: new evidence and future perspectives

Goycochea-Valdivia WA, Capilla MA, García MC

Language: Spanish
References: 12
Page: 60-63
PDF size: 214.36 Kb.





REFERENCES

  1. Semon AK, Keenan O, Zackular JP. Clostridioides difficile and the microbiota early in life. J Pediatric Infect Dis Soc. 2021; 10 (Supplement_3): S3-S7. doi: 10.1093/jpids/piab063.

  2. McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66 (7): e1-e48.

  3. Gonzales-Luna AJ, Carlson TJ, Garey KW. Antibiotic therapies for Clostridioides difficile infection in children. J Pediatric Infect Dis Soc. 2021; 10 (Supplement_3): S52-S57.

  4. D'Ostroph AR, So TY. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist. 2017; 10: 365-375.

  5. Sammons JS, Toltzis P, Zaoutis TE. Clostridium difficile infection in children. JAMA Pediatr. 2013; 167 (6): 567-573.

  6. Lo Vecchio A, Lancella L, Tagliabue C et al. Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country. Eur J Clin Microbiol Infect Dis. 2017; 36: 177-185.

  7. Yin J, Kociolek LK, Same RG, Hsu AJ, Amoah J, Tamma PD. Oral vancomycin may be associated with earlier symptom resolution than metronidazole for hospitalized children with nonsevere Clostridiodes difficile infections. Open Forum Infect Dis. 2019; 6 (12): ofz492.

  8. Wolf J, Kalocsai K, Fortuny C et al. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis. 2020; 71: 2581-2588.

  9. Sattler MM, Crews JD. Challenges in the diagnosis and management of recurrent and severe Clostridioides difficile infection in children. J Pediatric Infect Dis Soc. 2021; 10 (Supplement_3): S27-S33.

  10. Bernard R, Hourigan SK, Nicholson MR. Fecal microbiota transplantation and microbial therapeutics for the treatment of Clostridioides difficile infection in pediatric patients. J Pediatric Infect Dis Soc. 2021; 10 (Supplement_3): S58-S63.

  11. Wilcox MH, Gerding DN, Poxton IR et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017; 376: 305-317.

  12. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014; 10 (6): 1466-1477.




2020     |     www.medigraphic.com